The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and
10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks
of treatment in Asian subjects with moderate to severe chronic plaque psoriasis who are
candidates for systemic therapy or phototherapy.

Clinical Trial Conditions: Psoriasis

Treatments in this Clinical Trial : Placebo, CP-690,550, CP-690,550

Clinical Trial Phase: Phase 3

Eligible Clinical Trial Participant Age : Between 18 years to 100 years

Can Healthy Volunteers Participate: No

Clinical Trial Lead Sponsor: Pfizer

Detailed Clinical Trial Description: The primary objective of this study is to compare the efficacy of CP-690,550 (5 mg BID and
10 mg BID) versus placebo for the reduction in severity of plaque psoriasis after 16 weeks
of treatment in Asian subjects with moderate to severe chronic plaque psoriasis who are
candidates for systemic therapy or phototherapy.

The clinical trial information was obtained from http://clinicaltrials.gov/ct2/show/NCT01815424